SARKKOS Therapeutics is an early-stage biotechnology company pioneering the development of first-in-class small molecule inhibitors that target the molecular drivers of obesity-associated solid tumours.
Our Mission
Our mission is to bridge the gap between metabolic dysfunction and oncology with scientifically validated mechanism-based targeted therapies for the benefit of obese patients suffering from solid cancer. We aim to develop innovative, targeted anti-tumour therapies that address the unique biological challenges of obesity-related solid cancers, improving survival and quality of life for underserved patient populations.
About Us
The team has diverse professional experiences across the biotech and research ecosystem and strategic innovation, ensuring a holistic approach to advancing groundbreaking therapies and transforming patient outcomes.
Dr Renaud Quantin
Chief Executive Officer
Dr Dominic De Nardo
External Research Collaborator
Group Leader · Monash University